Science Advances · 2020 · 108 citations · 41 references
MedicineCancer BiologyOncologyCarcinogenesisDna RepairMolecular OncologyDna DamageDna Damage SignalingRadiation TherapySynthetic LethalitySynthetic Lethality In CancerTargeted Cancer TherapyChemical Synthetic LethalityDna Damage Repair PathwaysDna Repair Synthetic LethalityIsocitrate Dehydrogenase MutationsParp InhibitionParp Inhibitor SensitivityPoly Adp-ribose Polymerase InhibitorsPoly(adp-ribose) Polymerase Inhibitors
Mutations in isocitrate dehydrogenase (IDH) genes occur in multiple cancer types, lead to global changes in the epigenome, and drive tumorigenesis. Yet, effective strategies targeting solid tumors harboring IDH mutations remain elusive. Here, we demonstrate that IDH-mutant gliomas and cholangiocarcinomas display elevated DNA damage. Using multiple in vitro and preclinical animal models of glioma and cholangiocarcinoma, we developed treatment strategies that use a synthetic lethality approach targeting the reduced DNA damage repair conferred by mutant IDH using poly(adenosine 5'-diphosphate) ribose polymerase inhibitors (PARPis). The therapeutic effects are markedly enhanced by cotreatment with concurrent, localized radiation therapy. PARPi-buttressed multimodality therapies may represent a readily applicable approach that is selective for IDH-mutant tumor cells and has potential to improve outcomes in multiple cancers.
41
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons, Siân Jones, Xiaosong Zhang et al. · Science · 2008 · 5.8K citations · Full text
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan W. Valle, Harpreet Wasan, Daniel H. Palmer et al. · New England Journal of Medicine · 2010 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +12